Parkinson’s Disease: Etiology, Neuropathology, and Pathogenesis

Antonina Kouli, Kelli M. Torsney, Wei-Li Kuan, Thomas B. Stoker, Julia C. Greenland, Antonina Kouli, Kelli M. Torsney, Wei-Li Kuan, Thomas B. Stoker, Julia C. Greenland

Excerpt

Parkinson’s disease (PD) is a common neurodegenerative disorder. While a number of non-motor manifestations arise, the typical clinical features involve a movement disorder consisting of bradykinesia, resting tremor, and rigidity, with postural instability occurring at a later stage. The cause of PD is not known, but a number of genetic risk factors have now been characterized, as well as several genes which cause rare familial forms of PD. Environmental influences such as smoking, caffeine consumption, and pesticide exposure have been postulated to alter the risk of PD development, although the role of these remains unclear. The movement disorder arises due to the loss of dopaminergic neurons of the substantia nigra pars compacta, with the pathological hallmark being intracellular aggregates of α-synuclein, in the form of Lewy bodies and Lewy neurites. Several processes have been implicated in PD, including mitochondrial dysfunction, defective protein clearance mechanisms, and neuroinflammation, but the way in which these factors interact remains incompletely understood.

Copyright: The Authors.

References

    1. Kalia LV, Lang AE. Parkinson’s disease. Lancet. 2015 Aug 29;386(9996):896–912. .
    1. Tanner CM, Goldman SM. Epidemiology of Parkinson’s disease. Neurol Clin. 1996 May;14(2):317–35. .
    1. Nussbaum RL, Ellis CE. Alzheimer’s disease and Parkinson’s disease. N Engl J Med. 2003 Apr 3;348(14):1356–64. .
    1. Chen RC, Chang SF, Su CL, Chen TH, Yen MF, Wu HM, et al. Prevalence, incidence, and mortality of PD: A door-to-door survey in Ilan county, Taiwan. Neurology. 2001 Nov 13;57(9):1679–86. .
    1. Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, et al. Identifying prodromal Parkinson’s disease: Pre-motor disorders in Parkinson’s disease. Mov Disord. 2012 Apr 15;27(5):617–26. .
    1. Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology. 2008 Aug 12;71(7):474–80. .
    1. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study. Lancet Neurol. 2015 Jan;14(1):57–64. .
    1. Ma SY, Röyttä M, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson’s disease using disector counts. J Neurol Sci. 1997 Oct 3;151(1):83–7. .
    1. Williams-Gray CH, Worth PF. Parkinson’s disease. Medicine. 2016 Sep 1;44(9):542–6. .
    1. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, et al. Variable expression of Parkinson’s disease: A base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology. 1990 Oct;40(10):1529–34. .
    1. Marras C, Lang A. Parkinson’s disease subtypes: Lost in translation? J Neurol Neurosurg Psychiatr. 2013;84(4):409–415. .
    1. Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR. NMSS Validation Group. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011 Feb 15;26(3):399–406. .
    1. Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, et al. Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: An observational cohort study. Lancet Neurol. 2013 May;12(5):443–53. .
    1. Noyce AJ, Bestwick JP, Silveira-Moriyama L, Hawkes CH, Giovannoni G, Lees AJ, et al. Meta-analysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol. 2012 Dec;72(6):893–901. .
    1. Lees AJ, Hardy J, Revesz T. Parkinson’s disease. Lancet. 2009 Jun 13;373(9680):2055–66. .
    1. de Rijk MC, Breteler MM, Graveland GA, Ott A, Grobbee DE, van der Meché FG, et al. Prevalence of Parkinson’s disease in the elderly: The Rotterdam Study. Neurology. 1995 Dec;45(12):2143–6. .
    1. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology. 1999 Apr 12;52(6):1214–20. .
    1. Grandinetti A, Morens DM, Reed D, MacEachern D. Prospective study of cigarette smoking and the risk of developing idiopathic Parkinson’s disease. Am J Epidemiol. 1994 Jun 15;139(12):1129–38. .
    1. Paganini-Hill A. Risk factors for Parkinson’s disease: The leisure world cohort study. Neuroepidemiology. 2001 May;20(2):118–24. .
    1. Hernán MA, Zhang SM, Rueda-deCastro AM, Colditz GA, Speizer FE, Ascherio A. Cigarette smoking and the incidence of Parkinson’s disease in two prospective studies. Ann Neurol. 2001 Dec;50(6):780–6. .
    1. Hernán MA, Takkouche B, Caamaño-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann Neurol. 2002 Sep;52(3):276–84. .
    1. Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007 Jul;64(7):990–7. .
    1. Breckenridge CB, Berry C, Chang ET, Jr RLS, Mandel JS. Association between Parkinson’s disease and cigarette smoking, rural living, well-water consumption, farming and pesticide use: Systematic review and meta-analysis. PLoS One. 2016 Apr 7;11(4):e0151841. .
    1. Bordia T, McGregor M, Papke RL, Decker MW, McIntosh JM, Quik M. The α7 nicotinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions. Exp Neurol. 2015 Jan;263:277–84. .
    1. Srinivasan R, Henley BM, Henderson BJ, Indersmitten T, Cohen BN, Kim CH, et al. Smoking-relevant nicotine concentration attenuates the unfolded protein response in Dopaminergic neurons. J Neurosci. 2016 Jan 6;36(1):65–79. .
    1. Ritz B, Lee P-C, Lassen CF, Arah OA. Parkinson disease and smoking revisited: Ease of quitting is an early sign of the disease. Neurology. 2014 Oct 14;83(16):1396–402. .
    1. Ross GW, Abbott RD, Petrovitch H, Morens DM, Grandinetti A, Tung KH, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000 May 24;283(20):2674–9. .
    1. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, et al. Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson’s disease. J Neurosci. 2001 May 15;21(10):RC143. .
    1. Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, et al. Prospective study of caffeine consumption and risk of Parkinson’s disease in men and women. Ann Neurol. 2001 Jul;50(1):56–63. .
    1. Benedetti MD, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Smoking, alcohol, and coffee consumption preceding Parkinson’s disease: A case-control study. Neurology. 2000 Nov 14;55(9):1350–8. .
    1. Ascherio A, Weisskopf MG, O’Reilly EJ, McCullough ML, Calle EE, Rodriguez C, et al. Coffee consumption, gender, and Parkinson’s disease mortality in the cancer prevention study II cohort: The modifying effects of estrogen. Am J Epidemiol. 2004 Nov 15;160(10):977–84. .
    1. Xu K, Xu Y, Brown-Jermyn D, Chen J-F, Ascherio A, Dluzen DE, et al. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J Neurosci. 2006 Jan 11;26(2):535–41. .
    1. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983 Feb 25;219(4587):979–80.
    1. Elbaz A, Clavel J, Rathouz PJ, Moisan F, Galanaud J-P, Delemotte B, et al. Professional exposure to pesticides and Parkinson disease. Ann Neurol. 2009 Oct;66(4):494–504. .
    1. Di Monte D, Sandy MS, Ekström G, Smith MT. Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP+) cytotoxicity. Biochem Biophys Res Comm. 1986 May 29;137(1):303–9.
    1. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT. Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci. 2000 Dec;3(12):1301–6. .
    1. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, Paraquat, and Parkinson’s disease. Environ Health Perspect. 2011 Jun;119(6):866–72. .
    1. Deng H, Wang P, Jankovic J. The genetics of Parkinson disease. Ageing Res Rev. 2018 Mar 1;42:72–85. .
    1. Schulte C, Gasser T. Genetic basis of Parkinson’s disease: Inheritance, penetrance, and expression. Appl Clin Genet. 2011 Jun 1;4:67–80.
    1. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology. 2009 Jan 27;72(4):310–16. .
    1. Sidransky E, Lopez G. The link between the GBA gene and parkinsonism. Lancet Neurol. 2012 Nov;11(11):986–98. .
    1. Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease. Nat Genet. 2014 Jul 27;46(9):989–93. .
    1. Simón-Sánchez J, Schulte C, Bras JM, Sharma M, Gibbs JR, Berg D, et al. Genome-wide association study reveals genetic risk underlying Parkinson’s disease. Nat Genet. 2009 Dec;41(12):1308–12. .
    1. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science. 1997 Jun 27;276(5321):2045–7. .
    1. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, et al. α-Synuclein locus triplication causes Parkinson’s disease. Science. 2003 Oct 31;302(5646):841. .
    1. Zarranz JJ, Alegre J, Gómez-Esteban JC, Lezcano E, Ros R, Ampuero I, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004 Feb;55(2):164–73. .
    1. Chartier-Harlin M-C, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, et al. Alpha-synuclein locus duplication as a cause of familial Parkinson’s disease. Lancet. 2004 Oct 25;364(9440):1167–9. .
    1. Krüger R, Kuhn W, Müller T, Woitalla D, Graeber M, Kösel S, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat Genet. 1998 Feb;18(2):106–8. .
    1. Appel-Cresswell S, Vilarino-Guell C, Encarnacion M, Sherman H, Yu I, Shah B, et al. Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s disease. Mov Disord. 2013 Jun;28(6):811–13. .
    1. Lesage S, Anheim M, Letournel F, Bousset L, Honoré A, Rozas N, et al. G51D α-synuclein mutation causes a novel Parkinsonian–pyramidal syndrome. Ann Neurol. 2013 Mar 22;73(4):459–71. .
    1. Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: A case-control study. Lancet Neurol. 2008 Jul;7(7):583–90. .
    1. Pickrell AM, Youle RJ. The roles of PINK1, Parkin and mitochondrial fidelity in Parkinson’s disease. Neuron. 2015 Jan 21;85(2):257–73. .
    1. Ramirez A, Heimbach A, Gründemann J, Stiller B, Hampshire D, Cid LP, et al. Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet. 2006 Oct;38(10):1184–91. .
    1. Paisan-Ruiz C, Bhatia KP, Li A, Hernandez D, Davis M, Wood NW, et al. Characterization of PLA2G6 as a locus for dystonia-parkinsonism. Ann Neurol. 2009 Jan;65(1):19–23. .
    1. Di Fonzo A, Dekker MCJ, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L, et al. FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome. Neurology. 2009 Jan 20;72(3):240–5. .
    1. Olgiati S, Quadri M, Fang M, Rood JPMA, Saute JA, Chien HF, et al. DNAJC6 mutations associated with early-onset Parkinson’s disease. Ann Neurol. 2016 Feb 1;79(2):244–56. .
    1. Puschmann A, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, Cobb SA, et al. A Swedish family with de novo alpha-synuclein A53T mutation: Evidence for early cortical dysfunction. Parkinsonism Relat Disord. 2009 Nov;15(9):627–32. .
    1. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998 Apr 9;392(6676):605–8. .
    1. Nishikawa K, Li H, Kawamura R, Osaka H, Wang Y-L, Hara Y, et al. Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun. 2003 Apr 25;304(1):176–83. .
    1. Valente EM, Salvi S, Ialongo T, Marongiu R, Elia AE, Caputo V, et al. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann Neurol. 2004 Sep;56(3):336–41. .
    1. Bonifati V, Rizzu P, van Baren MJ, Schaap O, Breedveld GJ, Krieger E, et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science. 2003 Jan 10;299(5604):256–9. .
    1. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron. 2004 Nov 18;44(4):601–7. .
    1. Williams DR, Hadeed A, al-Din ASN, Wreikat A-L, Lees AJ. Kufor Rakeb disease: Autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord. 2005 Oct;20(10):1264–71. .
    1. Lautier C, Goldwurm S, Dürr A, Giovannone B, Tsiaras WG, Pezzoli G, et al. Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease. Am J Hum Genet. 2008 Apr;82(4):822–33. .
    1. Strauss KM, Martins LM, Plun-Favreau H, Marx FP, Kautzmann S, Berg D, et al. Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson’s disease. Hum Mol Genet. 2005 Aug 1;14(15):2099–111. .
    1. Wider C, Skipper L, Solida A, Brown L, Farrer M, Dickson D, et al. Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. Parkinsonism Relat Disord. 2008 Aug;14(6):465–70. .
    1. Chartier-Harlin M-C, Dachsel JC, Vilariño-Güell C, Lincoln SJ, Leprêtre F, Hulihan MM, et al. Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet. 2011 Sep 9;89(3):398–406. .
    1. Quadri M, Fang M, Picillo M, Olgiati S, Breedveld GJ, Graafland J, et al. Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism. Hum Mutat. 2013 Sep;34(9):1208–15. .
    1. Vilariño-Güell C, Rajput A, Milnerwood AJ, Shah B, Szu-Tu C, Trinh J, et al. DNAJC13 mutations in Parkinson disease. Hum Mol Genet. 2014 Apr 1;23(7):1794–801. .
    1. Lesage S, Drouet V, Majounie E, Deramecourt V, Jacoupy M, Nicolas A, et al. Loss of VPS13C function in autosomal-recessive Parkinsonism causes mitochondrial dysfunction and increases PINK1/Parkin-dependent Mitophagy. Am J Hum Genet. 2016 Mar 3;98(3):500–13. .
    1. Dickson DW. Parkinson’s disease and Parkinsonism: Neuropathology. Cold Spring Harb Perspect Med. 2012 Aug 1;2(8):a009258. .
    1. Fearnley JM, Lees AJ. Ageing and Parkinson’s disease: Substantia nigra regional selectivity. Brain. 1991 Oct;114(Pt 5):2283–301. .
    1. Greffard S, Verny M, Bonnet A-M, Beinis J-Y, Gallinari C, Meaume S, et al. Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol. 2006 Apr;63(4):584–8. .
    1. Cheng H-C, Ulane CM, Burke RE. Clinical progression in Parkinson’s disease and the neurobiology of axons. Ann Neurol. 2010 Jun;67(6):715–25. .
    1. Rudow G, O’Brien R, Savonenko AV, Resnick SM, Zonderman AB, Pletnikova O, et al. Morphometry of the human substantia nigra in ageing and Parkinson’s disease. Acta Neuropathol. 2008 Feb 23;115(4):461. .
    1. Giguère N, Burke Nanni S, Trudeau L-E. On cell loss and selective vulnerability of neuronal populations in Parkinson’s disease. Front Neurol [Internet]. 2018 [cited 2018 Oct 18];9. Available from. .
    1. Kordower JH, Olanow CW, Dodiya HB, Chu Y, Beach TG, Adler CH, et al. Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease. Brain. 2013 Aug 1;136(8):2419–31. .
    1. Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson’s disease: Review of recent trials. Mov Disord. 2013 Feb 1;28(2):131–44. .
    1. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: Diagnosis and management. Lancet Neurol. 2006 Mar;5(3):235–45. .
    1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997 Aug 28;388(6645):839–40. .
    1. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6469–73. .
    1. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2012 Nov 27;9(1):13–24. .
    1. Xia Q, Liao L, Cheng D, Duong DM, Gearing M, Lah JJ, et al. Proteomic identification of novel proteins associated with Lewy bodies. Front Biosci. 2008 May 1;13:3850–6. .
    1. Braak H, Del Tredici K, Rüb U, de Vos RA, Steur ENJ, Braak E. Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging. 2003;24(2):197–211. .
    1. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: Dopaminergic pathophysiology and treatment. Lancet Neurol. 2009 May;8(5):464–74. .
    1. Khoo TK, Yarnall AJ, Duncan GW, Coleman S, O’Brien JT, Brooks DJ, et al. The spectrum of nonmotor symptoms in early Parkinson disease. Neurology. 2013 Jan 15;80(3):276–81. .
    1. Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson’s disease: A longitudinal 18F-dopa PET study. Neuroimage. 2011 Jun 1;56(3):1463–8. .
    1. Hawkes CH, Tredici KD, Braak H. Parkinson’s disease: A dual-hit hypothesis. Neuropathol Appl Neurobiol. 2007 Dec 1;33(6):599–614. .
    1. Parkkinen L, Pirttilä T, Alafuzoff I. Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance. Acta Neuropathol. 2008 Apr 1;115(4):399–407. .
    1. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RKB. The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson’s disease: A critical analysis of α-synuclein staging. Neuropathol Appl Neurobiol. 2008 Jun 1;34(3):284–95. .
    1. Jellinger KA. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta. 2009 Jul;1792(7):730–40. .
    1. Surmeier DJ, Obeso JA, Halliday GM. Parkinson’s disease is not simply a prion disorder. J Neurosci. 2017 Oct 11;37(41):9799–807. .
    1. Bloch A, Probst A, Bissig H, Adams H, Tolnay M. α-Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006 Jun 1;32(3):284–95. .
    1. Beach TG, Adler CH, Sue LI, Vedders L, Lue L, White III CL, et al. Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders. Acta Neuropathol. 2010 Jun 1;119(6):689–702. .
    1. Beach TG, Carew J, Serrano G, Adler CH, Shill HA, Sue LI, et al. Phosphorylated α-synuclein-immunoreactive retinal neuronal elements in Parkinson’s disease subjects. Neurosci Lett. 2014 Jun 13;571:34–8. .
    1. Svensson E, Horváth-Puhó E, Thomsen RW, Djurhuus JC, Pedersen L, Borghammer P, et al. Vagotomy and subsequent risk of Parkinson’s disease. Ann Neurol. 2015 Oct 1;78(4):522–9. .
    1. Perez-Pardo P, Kliest T, Dodiya HB, Broersen LM, Garssen J, Keshavarzian A, et al. The gut-brain axis in Parkinson’s disease: Possibilities for food-based therapies. Eur J Pharmacol. 2017 Dec 15;817:86–95. .
    1. Jellinger KA, Popescu B. Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med. 2012 Jun;16(6):1166–83. .
    1. Elobeid A, Libard S, Leino M, Popova SN, Alafuzoff I. Altered proteins in the aging brain. J Neuropathol Exp Neurol. 2016 Apr;75(4):316–25. .
    1. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson’s disease brains with and without dementia. Exp Neurol. 2010 Sep;225(1):210–18. .
    1. Duka T, Sidhu A. The neurotoxin, MPP+, induces hyperphosphorylation of Tau, in the presence of α-Synuclein, in SH-SY5Y neuroblastoma cells. Neurotox Res. 2006 Mar;10(1):1–10.
    1. Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, Goudreau JL, et al. Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J. 2006 Nov;20(13):2302–12. .
    1. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJG, Brown J, et al. Tau and α-synuclein in susceptibility to, and dementia in, Parkinson’s disease. Ann Neurol. 2007 Aug;62(2):145–53. .
    1. Lashley T, Holton JL, Gray E, Kirkham K, O’Sullivan SS, Hilbig A, et al. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson’s disease patients. Acta Neuropathol. 2008 Apr;115(4):417–25. .
    1. Pletnikova O, West N, Lee MK, Rudow GL, Skolasky RL, Dawson TM, et al. AA deposition is associated with enhanced cortical α-synuclein lesions in Lewy body diseases. Neurobiol Aging. 2005 Aug;26(8):1183–92. .
    1. Kalaitzakis ME, Graeber MB, Gentleman SM, Pearce RKB. Striatal β-Amyloid deposition in Parkinson disease with dementia. J Neuropathol Exp Neurol. 2008 Feb 1;67(2):155–61. .
    1. Compta Y, Parkkinen L, O’Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy- and Alzheimer-type pathologies in Parkinson’s disease dementia: Which is more important? Brain. 2011 May 1;134(5):1493–505. .
    1. Ruffmann C, Calboli FCF, Bravi I, Gveric D, Curry LK, de Smith A, et al. Cortical Lewy bodies and AA burden are associated with prevalence and timing of dementia in Lewy body diseases. Neuropathol Appl Neurobiol. 2016 Aug;42(5):436–50.
    1. Burré J, Vivona S, Diao J, Sharma M, Brunger AT, Südhof TC. Properties of native brain α-synuclein. Nature. 2013 Jun;498(7453):E4–6. .
    1. Bartels T, Choi JG, Selkoe DJ. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature. 2011 Sep;477(7362):107–10. .
    1. Eliezer D, Kutluay E, Bussell R, Browne G. Conformational properties of α-synuclein in its free and lipid-associated states11Edited by P. E. Wright. J Mol Biol. 2001 Apr 6;307(4):1061–73.
    1. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002 Feb;4(2):160–4. .
    1. Barrett PJ, Timothy Greenamyre J. Post-translational modification of α-synuclein in Parkinson’s disease. Brain Res. 2015 Dec 2;1628(Pt B):247–53.
    1. Baba M, Nakajo S, Tu PH, Tomita T, Nakaya K, Lee VM, et al. Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am J Pathol. 1998 Apr;152(4):879–84.
    1. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, et al. In vivo demonstration that -synuclein oligomers are toxic. Proc Natl Acad Sci. 2011 Mar 8;108(10):4194–9. .
    1. Karpinar DP, Balija MBG, Kügler S, Opazo F, Rezaei-Ghaleh N, Wender N, et al. Pre-fibrillar α-synuclein variants with impaired β-structure increase neurotoxicity in Parkinson’s disease models. EMBO J. 2009 Oct 21;28(20):3256–68. .
    1. Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B. Seeding induced by α-synuclein oligomers provides evidence for spreading of α-synuclein pathology. J Neurochem. 2009 Oct 1;111(1):192–203. .
    1. Moon HE, Paek SH. Mitochondrial dysfunction in Parkinson’s disease. Exp Neurobiol. 2015 Jun;24(2):103–16. .
    1. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem. 1990 Mar;54(3):823–7. .
    1. Bindoff LA, Birch-Machin MA, Cartlidge NEF, Parker WD, Turnbull DM. Respiratory chain abnormalities in skeletal muscle from patients with Parkinson’s disease. J Neurol Sci. 1991 Aug 1;104(2):203–8. .
    1. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AH. Platelet mitochondrial function in Parkinson’s disease. The Royal Kings and Queens Parkinson Disease Research Group. Ann Neurol. 1992 Dec;32(6):782–8. .
    1. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D, et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure. Ann Neurol. 1999;46(4):598–605. .
    1. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 1985 Jul 1;36(26):2503–8. .
    1. Tanner CM, Kamel F, Ross GW, Hoppin JA, Goldman SM, Korell M, et al. Rotenone, paraquat, and Parkinson’s disease. Environ Health Perspect. 2011 Jun 1;119(6):866–72. .
    1. Valente EM, Bentivoglio AR, Dixon PH, Ferraris A, Ialongo T, Frontali M, et al. Localization of a novel locus for autosomal recessive early-onset Parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet. 2001 Apr;68(4):895–900. .
    1. Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK. Mitochondrial import and accumulation of α-Synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem. 2008 Apr 4;283(14):9089–100. .
    1. Luth ES, Stavrovskaya IG, Bartels T, Kristal BS, Selkoe DJ. Soluble, prefibrillar α-Synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J Biol Chem. 2014 Aug 1;289(31):21490–507. .
    1. Maio RD, Barrett PJ, Hoffman EK, Barrett CW, Zharikov A, Borah A, et al. α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci Transl Med. 2016 Jun 8;8(342):342ra78.
    1. Pan T, Kondo S, Le W, Jankovic J. The role of autophagy-lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain. 2008 Aug 1;131(8):1969–78. .
    1. Xilouri M, Brekk OR, Stefanis L. Alpha-synuclein and protein degradation systems: A reciprocal relationship. Mol Neurobiol. 2013 Apr 1;47(2):537–51. .
    1. Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Protein degradation pathways in Parkinson’s disease: Curse or blessing. Acta Neuropathol. 2012 Aug 1;124(2):153–72. .
    1. Lee H-J, Khoshaghideh F, Patel S, Lee S-J. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J Neurosci. 2004 Feb 25;24(8):1888–96. .
    1. McKinnon C, Tabrizi SJ. The Ubiquitin-Proteasome system in neurodegeneration. Antioxidants Redox Signaling. 2014 Jan 18;21(17):2302–21. .
    1. McNaught KSP, Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci Lett. 2001 Jan 19;297(3):191–4. .
    1. Ullrich C, Mlekusch R, Kuschnig A, Marksteiner J, Humpel C. Ubiquitin enzymes, ubiquitin and proteasome activity in blood mononuclear cells of MCI, Alzheimer and Parkinson patients. Curr Alzheimer Res. 2010 Sep;7(6):549–55. .
    1. McNaught KSP, Belizaire R, Jenner P, Olanow CW, Isacson O. Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci Lett. 2002 Jul 5;326(3):155–8. .
    1. McNaught KSP, Belizaire R, Isacson O, Jenner P, Olanow CW. Altered proteasomal function in sporadic Parkinson’s disease. Exp Neurol. 2003 Jan;179(1):38–46. .
    1. Um JW, Im E, Lee HJ, Min B, Yoo L, Yoo J, et al. Parkin directly modulates 26S proteasome activity. J Neurosci. 2010 Sep 1;30(35):11805–14. .
    1. Zeng B-Y, Iravani MM, Lin S-T, Irifune M, Kuoppamäki M, Al-Barghouthy G, et al. MPTP treatment of common marmosets impairs proteasomal enzyme activity and decreases expression of structural and regulatory elements of the 26S proteasome. Eur J Neurosci. 2006 Apr;23(7):1766–74. .
    1. Zeng B-Y, Bukhatwa S, Hikima A, Rose S, Jenner P. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats. Ann Neurol. 2006 Aug;60(2):248–52. .
    1. Bedford L, Hay D, Devoy A, Paine S, Powe DG, Seth R, et al. Depletion of 26S Proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci. 2008 Aug 13;28(33):8189–98. .
    1. Tanji K, Mori F, Kakita A, Takahashi H, Wakabayashi K. Alteration of autophagosomal proteins (LC3, GABARAP and GATE-16) in Lewy body disease. Neurobiol Dis. 2011 Sep 1;43(3):690–7. .
    1. Dehay B, Bove J, Rodriguez-Muela N, Perier C, Recasens A, Boya P, et al. Pathogenic lysosomal depletion in Parkinson’s disease. J Neurosci. 2010 Sep 15;30(37):12535–44. .
    1. Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH. Alterations in lysosomal and proteasomal markers in Parkinson’s disease: Relationship to alpha-synuclein inclusions. Neurobiol Dis. 2009 Sep;35(3):385–98. .
    1. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, Caballero C, Ferrer I, Obeso JA, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol. 2010 Dec;67(12):1464–72. .
    1. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology. 1988 Aug;38(8):1285–91. .
    1. Hunot S, Dugas N, Faucheux B, Hartmann A, Tardieu M, Debré P, et al. FcFRII/CD23 is expressed in Parkinson’s disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-f in Glial cells. J Neurosci. 1999 May 1;19(9):3440–7. .
    1. Loeffler DA, Camp DM, Conant SB. Complement activation in the Parkinson’s disease substantia nigra: An immunocytochemical study. J Neuroinflammation. 2006;3:29. .
    1. Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: A target for neuroprotection? Lancet Neurol. 2009;8(4):382–97. .
    1. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis. 2006 Feb;21(2):404–12. .
    1. Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Chaudhuri KR, et al. Microglia, amyloid, and glucose metabolism in Parkinson’s disease with and without dementia. Neuropsychopharmacology. 2013;38(6):938–49. .
    1. He Y, Appel S, Le W. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res. 2001 Aug 3;909(1–2):187–93. .
    1. Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi D-K, et al. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci. 2002;22(5):1763–71.
    1. Su X, Maguire-Zeiss KA, Giuliano R, Prifti L, Venkatesh K, Federoff HJ. Synuclein activates microglia in a model of Parkinson’s disease. Neurobiol Aging. 2008 Nov;29(11):1690–701.
    1. Saiki M, Baker A, Williams-Gray CH, Foltynie T, Goodman RS, Taylor CJ, et al. Association of the human leucocyte antigen region with susceptibility to Parkinson’s disease. J Neurol Neurosurg Psychiatr. 2010 Aug 1;81(8):890–1.
    1. Gao X, Chen H, Schwarzschild MA, Ascherio A. Use of ibuprofen and risk of Parkinson disease. Neurology. 2011;76(10):863–9.
    1. Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, et al. Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD) Mov Disord. 2016 Jul 1;31(7):995–1003.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner